Who are albiglutide + insulin glargine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Semaglutide Treatment, Continue GLP/GIP, Semaglutide Pen Injector, Semaglutide (Rybelsus®), SGLT2 inhibitor, GLP-1 RA, GLP-1 receptor agonist.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/albiglutide-insulin-glargine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

albiglutide + insulin glargine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

albiglutide + insulin glargine (albiglutide + insulin glargine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist and long-acting basal insulin analog. Area: Diabetes.

phase 3 GLP-1 receptor agonist and long-acting basal insulin analog GLP-1R Diabetes Biologic Live · refreshed every 30 min

Target snapshot

albiglutide + insulin glargine (albiglutide + insulin glargine) — GlaxoSmithKline. Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion, and insulin glargine is a long-acting basal insulin analog that provides a steady level of insulin throughout the day.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
albiglutide + insulin glargine TARGET	albiglutide + insulin glargine	GlaxoSmithKline	phase 3	GLP-1 receptor agonist and long-acting basal insulin analog	GLP-1R
Semaglutide Treatment	Semaglutide Treatment	University Health Network, Toronto	marketed	GLP-1 receptor agonist	GLP-1R
Continue GLP/GIP	Continue GLP/GIP	The Cleveland Clinic	marketed	GLP-1/GIP receptor agonist	GLP-1R, GIPR
Semaglutide Pen Injector	Semaglutide Pen Injector	University of Pennsylvania	marketed	GLP-1 receptor agonist	GLP-1R
Semaglutide (Rybelsus®)	Semaglutide (Rybelsus®)	Instituto Mexicano del Seguro Social	marketed	GLP-1 receptor agonist	GLP-1R (GLP-1 receptor)
SGLT2 inhibitor, GLP-1 RA	SGLT2 inhibitor, GLP-1 RA	Brigham and Women's Hospital	marketed	SGLT2 inhibitor / GLP-1 receptor agonist combination	SGLT2 and GLP-1R
GLP-1 receptor agonist	GLP-1 receptor agonist	Brigham and Women's Hospital	marketed	GLP-1 receptor agonist	GLP-1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist and long-acting basal insulin analog class)

GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). albiglutide + insulin glargine — Competitive Intelligence Brief. https://druglandscape.com/ci/albiglutide-insulin-glargine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab